Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CLEO Diagnostics Ltd ( (AU:COV) ) is now available.
Cleo Diagnostics Ltd has successfully completed alpha testing for its ovarian cancer pre-surgical triage test kit, a significant milestone towards commercial production. This achievement allows the company to proceed with assay optimization, beta testing, and manufacturing scale-up, in partnership with R&D Systems, to support FDA submission and improve time to market. The test addresses a critical unmet need, as ovarian cancer remains the deadliest cancer affecting women globally.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is a company operating in the ovarian cancer diagnostics industry. It focuses on developing pre-surgical triage test kits for ovarian cancer, aiming to improve diagnostic accuracy and clinical decision-making.
Average Trading Volume: 167,371
Technical Sentiment Signal: Buy
Learn more about COV stock on TipRanks’ Stock Analysis page.